MIJ invests in DiscGenics2020.02.14

We are pleased to announce that MIJ has invested in DiscGenics, a bio start-up company that is developing allogeneic regenerative medicine products for treating intervertebral disk degeneration.

DiscGenics’s main field of development is regenerative medicine products that regenerate intervertebral disc tissue in cases of degenerative disc disease. This condition is said to be one of the greatest un-met medical needs, with no definitive therapy currently available despite more than five million patients in Japan and the United States estimated to be suffering from degenerative disc disease in the lumbar spine. DiscGenics’ regenerative medicine for treating intervertebral disk degeneration using allogeneic stem cells derived from the nucleus pulposus intervertebral discs is expected to provide a highly cost effective treatment option that eliminates the need for major surgery.

Recent NEWS